171 results on '"Goyal, Vinod Kumar"'
Search Results
2. Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects
3. Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy
4. Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study
5. Niger (Guizotia Abyssinica (L. f.) Cass.) an Oilseed Crop under Biotic Stress
6. Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects
7. Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization
8. Hits and misses with animal models of narcolepsy and the implications for drug discovery
9. First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects
10. Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses
11. Masupirdine (SUVN‐502) for the Potential Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type: Preliminary Efficacy and Phase‐3 Study Design
12. Assessment of toxicity and tolerability of a combination vehicle; 5% Pharmasolve, 45% Propylene glycol and 50% Polyethylene glycol 400 in rats following repeated intravenous administration
13. Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, SUVN-502, in Healthy Young Adults and Elderly Subjects
14. 0609 Samelisant, Histamine 3 Receptor Agonist for the Potential Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy
15. Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders
16. Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease
17. Effects of Masupirdine (SUVN‐502) on Agitation/Aggression and Psychosis in Patients with Probable Alzheimer’s Disease: A Post Hoc Analysis
18. Effect of Concurrent Use of Memantine on The Efficacy of Masupirdine (SUVN‐502): A Post‐hoc Analysis of a Phase‐2 Randomized Placebo‐Controlled Study
19. Potential beneficial effects of masupirdine (SUVN‐502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses
20. 0624 Samelisant (SUVN-G3031), Baseline Characteristics from a Phase-2 Study Evaluating Efficacy and Safety in Patients with Narcolepsy
21. Samelisant (SUVN-G3031), a Histamine-3(H3) Receptor Inverse Agonist in Animal Models of Sleep Disorders (P1-1.Virtual)
22. Effect of masupirdine (SUVN‐502) on cognition in patients with moderate Alzheimer's disease: A randomized, double‐blind, phase 2, proof‐of‐concept study
23. Masupirdine (SUVN‐502): A promising clinical candidate for the management of agitation in Alzheimer’s dementia
24. Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer’s Disease
25. Short-term toxicity study of 1-aminobenzotraizole, a CYP inhibitor, in Wistar rats.
26. Masupirdine in combination with donepezil and memantine in patients with moderate Alzheimer's disease: Subgroup analyses of memantine regimen, plasma concentrations and duration of treatment
27. Masupirdine (SUVN‐502): Novel treatment option for the management of behavioral and psychological symptoms in patients with Alzheimer’s disease
28. SUVN‐I6107: A novel muscarinic M1 receptor‐positive allosteric modulator (M1‐PAM) for the treatment of cognitive deficits
29. Short-term toxicity study of 1-aminobenzotraizole, a CYP inhibitor, in Wistar rats
30. 0649 Samelisant Improves the Symptoms of Excessive Daytime Sleepiness in Narcolepsy: Results from a Phase-2 Study
31. P4-660: TRIPLE THERAPY WITH MASUPIRDINE (SUVN-502), A 5-HT6 ANTAGONIST, DONEPEZIL AND MEMANTINE IN MODERATE ALZHEIMER'S DISEASE: BASELINE PATIENT CHARACTERISTICS IN A PHASE-2A STUDY
32. P2-031: SAFETY, TOLERABILITY AND HUMAN PHARMACOKINETICS OF SUVN-502, A POTENT AND PURE 5-HT6 RECEPTOR ANTAGONIST
33. Determination of Clastogenic and Anticlastogenic Potential of Cuminum Cyminum Seed Oil Using in Vitro Micronucleus Assay in CHO-K1 Cells
34. 0053 SUVN-G3031: Safety, Tolerability and Pharmacokinetics of a Potent and Selective Histamine H3 Receptor Inverse Agonist - Single and Multiple Ascending Doses in Healthy Subjects
35. 0139 SUVN-G3031, A Potent and Selective Histamine H3 Receptor Inverse Agonist - Phase-2 Investigational New Drug for the Treatment of Narcolepsy - Differentiating Factors with Competitor Clinical Candidates
36. 1021 Samelisant: Clinician and Patient Global Impression from a Double-Blind, Phase-2 Study in Patients with Narcolepsy
37. P3‐044: SUVN‐502, A PURE 5‐HT6 RECEPTOR ANTAGONIST, ATTENUATES THE MEMORY DEFICIT CAUSED BY BILATERAL COMMON CAROTID ARTERY LIGATION
38. P1‐075: IN‐VIVO CHARACTERIZATION OF SUVN‐I2004: AN M 1 POSITIVE ALLOSTERIC MODULATOR (PAM) IN ANIMAL MODELS OF COGNITION AND SAFETY
39. [P2-033]: SUVN-502 + DONEPEZIL + MEMANTINE (TRIPLE COMBINATION) REPRESENTS A PROMISING NEW APPROACH FOR SYMPTOMATIC TREATMENT OF ALZHEIMER's DISEASE
40. [P1-063]: SUVN-G3031, A SELECTIVE H3 RECEPTOR INVERSE AGONIST: ASSESSMENT OF SAFETY, TOLERABILITY AND PHARMACOKINETICS IN HEALTHY HUMAN VOLUNTEERS
41. [P1-460]: SUVN-D4010: A POTENT AND SELECTIVE 5-HT4 RECEPTOR PARTIAL AGONIST- ASSESSMENT OF SAFETY, TOLERABILITY AND PHARMACOKINETICS IN HEALTHY HUMAN VOLUNTEERS
42. TRIPLE THERAPY WITH MASUPIRDINE (SUVN-502), A 5-HT6 ANTAGONIST, DONEPEZIL AND MEMANTINE IN MODERATE ALZHEIMER'S DISEASE: BASELINE PATIENT CHARACTERISTICS IN A PHASE-2A STUDY
43. SAFETY, TOLERABILITY AND HUMAN PHARMACOKINETICS OF SUVN-502, A POTENT AND PURE 5-HT6 RECEPTOR ANTAGONIST
44. Spontaneous Congenital Hydrocephalus in Sprague Dawley Rat
45. Evaluation of clinical chemistry analytes from a single mouse using diluted plasma: effective way to reduce the number of animals in toxicity studies
46. P2-026: SUVN-G3031, a Potent and Selective H3 Receptor Inverse Agonist: Safety, Tolerability and Pharmacokinetics in Humans
47. P3-135: SUVN-I4035 - Preclinical Characterization of Novel Muscarinic M1 Positive Allosteric Modulator
48. P3-016: SUVN-D4010, A Potent and Selective 5-HT4 Receptor Partial Agonist: Safety, Tolerability and Pharmacokinetics in Humans
49. P1-085: SUVN-502, Potent and Pure 5-HT6 Receptor Antagonist: Proof-of-Concept Study Design in Moderate Alzheimer’s Disease Patients
50. SUVN-502, A PURE 5-HT6 RECEPTOR ANTAGONIST, ATTENUATES THE MEMORY DEFICIT CAUSED BY BILATERAL COMMON CAROTID ARTERY LIGATION
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.